Left Menu
Development News Edition

Rival drugmakers launch joint trial of medicines for COVID-19

"We wanted a trial to be able to quickly sift through multiple agents and prioritize." The study is a collaboration among pharmaceutical industry members of the recently-formed COVID Research & Development Alliance, Quantum Leap Healthcare Collaborative, a partnership of medical researchers and investors, and the Food and Drug Administration. The first segment will test whether Amgen's psoriasis drug Otezla, Takeda's anti-inflammatory Firazyr and AbbVie's cenicriviroc, which has been tried in patients with HIV, will help with the overactive, and potentially damaging, immune response that sometimes happens in patients with severe COVID-19.

Reuters | Updated: 03-08-2020 15:18 IST | Created: 03-08-2020 15:16 IST
Rival drugmakers launch joint trial of medicines for COVID-19
Representative Image Image Credit: ANI

Rival drugmakers AbbVie Inc, Amgen Inc and Takeda Pharmaceuticals Inc on Monday said they have begun treating patients in a trial to quickly show whether a drug from each company can be repurposed and used against COVID-19, the disease caused by the novel coronavirus.

The COVID-19 pandemic is an "all hands on deck moment," David Reese, Amgen's research and development chief told Reuters. "We wanted a trial to be able to quickly sift through multiple agents and prioritize." The study is a collaboration among pharmaceutical industry members of the recently-formed COVID Research & Development Alliance, Quantum Leap Healthcare Collaborative, a partnership of medical researchers and investors, and the Food and Drug Administration.

The first segment will test whether Amgen's psoriasis drug Otezla, Takeda's anti-inflammatory Firazyr and AbbVie's cenicriviroc, which has been tried in patients with HIV, will help with the overactive, and potentially damaging, immune response that sometimes happens in patients with severe COVID-19. The study's "adaptive platform" means several treatment candidates can be tested at the same time, with the most promising moving forward and the least promising dropping out, Quantum Leap co-founder Dr. Laura Esserman told Reuters.

"We could have some results in as early as six weeks," she said, adding that additional drugs will soon be added to the roster. Company officials said Otezla may be able to suppress inflammation from an overactive immune response; Firazyr may help limit fluid in the lungs; and cenicriviroc, which blocks activity of certain immune system cells, could reduce the severity of acute respiratory distress caused by the virus.

The drugs are being dosed in combination with Gilead Sciences Inc's antiviral drug remdesivir and generic steroid dexamethasone, both of which have been shown in rigorous trials to help COVID-19 patients and are now considered to be standard care, Dr. Esserman said. A comparison group of patients will be given remdesivir and dexamethasone alone. Hospitals have tried other anti-inflammatory drugs in COVID-19 patients, including Regeneron's Kevzara and Roche Holding's Actemra, but trials of both arthritis drugs failed to show effectiveness. Roche is continuing to test Actemra in combination with remdesivir.

The National Institute of Allergy and Infectious Diseases' ongoing adaptive COVID-19 trial is studying remdesivir in combination with Olumiant, an arthritis drug sold by Eli Lilly & Co. Those results are expected next month. Since the outbreak began seven months ago, so far killing more than 675,000 people worldwide, hundreds of clinical trials have been launched around the world to test whether existing drugs or experimental compounds could be effective treatments.

"There are a huge number of trials that for all the best intentions have been stood up around the world, but many are smaller - what we would call underpowered - and will not provide definitive answers," Amgen's Reese said. (Reporting By Deena Beasley; Editing by Aurora Ellis)


TRENDING

OPINION / BLOG / INTERVIEW

South Africa's COVID-19 response: Surprising outcomes or just poor data management?

South Africa has been committed to improving its health information system and shows that a robust digital has considerable scope to improve healthcare for the entire population. But the COVID-19 pandemic has highlighted that significant ga...

Post-COVID-19 Nigeria needs a robust Health Management Information System to handle high disease burden

Nigeria is among a few countries that conceptualised a health management information system HMIS in the early 90s but implementation has been a challenge till date. Besides COVID-19, the country has a huge burden of communicable and non-com...

Morocco COVID-19 response: A fragile health system and the deteriorating situation

Learning from its European neighbors, Morocco imposed drastic measures from the initial stages of the COVID-19 outbreak to try to contain its spread. The strategy worked for a few months but the cases have surged after mid-June. In this sit...

COVID-19: Argentina’s health system inefficiencies exaggerate flaws of health information system

You can recover from a drop in the GDP, but you cant recover from death, was the straightforward mindset of Argentinas President Alberto Fernndez and defined the countrys response to COVID-19. The South American nation imposed a strict...

Videos

Latest News

MNS workers protest in Navi Mumbai against toll fee hike

Maharashtra Navnirman Sena MNS workers on Thursday protested in Navi Mumbai against the Maharashtra governmens decision to increase toll fees. A few days back, the state government announced a hike in toll charges at all entry points of Mum...

Tokyo Stock Exchange suspends day's trade after worst-ever system glitch

Share trading in Japan was suspended for the entire day on Thursday after the Tokyo Stock Exchange suffered its worst technical outage in history, leaving investors unsure when trading will resume in the worlds third-largest stock market.Th...

Senate approves bill to avoid shutdown, sending it to Trump

By a sweeping bipartisan vote Wednesday, the Senate sent President Donald Trump a bill to fund the government through December 11, averting the possibility of a government shutdown when the new fiscal year starts Thursday. Trump was expecte...

NBA-Lakers dominate Heat for lopsided win in Game 1

Heavy favorites Los Angeles Lakers overcame a sluggish start to dismantle the Miami Heat 116-98 in Game 1 of the NBA Finals on Wednesday. The Heat got a 13-point leg up in the first quarter but the lead was shortlived, as the Lakers drained...

Give Feedback